This includes the use of small molecule MCL-1 inhibitors and knock-down/knock-out of MCL-1 in vitro and in vivo xenograft/genetically engineered mouse models to investigate the therapeutic potential of targeting MCL-1 in breast cancer. Here, MCL1 is linked to breast cancer.